Barings’s iShares Biotechnology ETF IBB Stock Holding History

Barings’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-13,128	Closed	-$1.28M	–	882
2017 Q1	$1.28M	Buy	13,128 +10,128	+338%	+$970K	0.03%	477
2016 Q4	$265K	Hold	3,000	–	–	0.01%	797
2016 Q3	$289K	Buy	+3,000	New	+$285K	0.01%	693

Other funds holding IBB

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Churchill Management Los Angeles, California $9.21B AUM 19.91% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Barings's IBB Position: Q2 2017 in Review

Barings sold out of iShares Biotechnology ETF (IBB) in Q2 2017, closing a stake of 13,128 shares — an estimated $1.28M sold.

Barings first reported a position in IBB in Q3 2016 and held it in 3 quarters. The position peaked at $1.28M in Q1 2017. 562 funds tracked by Wall St. Rank hold IBB as of Q2 2017.

Barings reported no remaining iShares Biotechnology ETF position as of Q2 2017 after selling out during the quarter.
Barings sold 13,128 iShares Biotechnology ETF shares in Q2 2017, an estimated $1.28M.
Barings first reported a position in iShares Biotechnology ETF in Q3 2016 and held it in 3 quarters.
Barings's iShares Biotechnology ETF position peaked at $1.28M in Q1 2017.
562 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2017.

Based on Barings's 13F filing for Q2 2017, filed 14 Aug 2017.